Nature has published their April 2022 Biopharma Dealmakers collection on the Advances in Artificial Intelligence-Driven Drug Development presenting companies “harnessing the power of artificial intelligence for the development of cutting-edge tools and novel approaches to accelerate drug discovery and research”.
We are very excited to have three Selvedge Venture Life Sciences AI companies featured in this collection! Click the links below to view the individual articles:
BIOS Health: Using data-driven insigths from the nrevous system to build neural digital therapies
Exogene Ltd: How artificial intelligence is enabling T cell receptor screening for cell therapy discovery
Multiomic Health Limited: Leveraging deep omics data to tackle a global health challenge with precision